Research programme: amino acids therapeutics - Axcella

Drug Profile

Research programme: amino acids therapeutics - Axcella

Alternative Names: DAACS™; Defined Amino Acid Compositions

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Axcella Health
  • Class Amino acids peptides and proteins
  • Mechanism of Action Amino acid replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Epilepsy; Muscular atrophy; Myotonic dystrophy; Non-alcoholic fatty liver disease

Most Recent Events

  • 14 Sep 2017 Axcella Health plans multiple proof-of-concept trials in last quarter of 2017
  • 04 Jan 2017 Preclinical trials in Epilepsy in USA (unspecified route)
  • 04 Jan 2017 Preclinical trials in Muscular atrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top